Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03944148
Other study ID # G19-00001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2019
Est. completion date December 30, 2019

Study information

Verified date December 2019
Source Hospital Universitario Dr. Jose E. Gonzalez
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Upper Gastrointestinal bleeding (UGIB) is a medical emergency and the most common cause of hospitalization associated with digestive disease. Proper initial resuscitation is the first step in the management of UGIB patients. Today, modern pulmonary ultrasound is used in different clinical settings, such as intensive care, emergency medicine and/or traumatology. In the last years, the use of this has been standardized both in internal medicine and in pulmonary medicine. The primary objective is to describe the findings of pulmonary ultrasound and its relationship with severity in patients with UGIB. The investigators will include all patients with UGIB. A pulmonary and vena cava ultrasound will be performed on admission to the emergency room, 10 minutes prior to endoscopy and 24 hours after having performed the endoscopy.

The use of thoracic point-of-care ultrasound (TPOCUS) has been standardized in both internal and pulmonary medicine. There is a concern about the role of TPOCUS useful as a severity prognostic tool in patients with UGIB.

The team proposes that TPOCUS is a severity prognostic tool in UGIB patients.

Main Outcome: To describe the findings of TPOCUS in patients with variceal and non-variceal UGIB.

Secondary Objectives:

1. Correlate the presence of B-type lines on TPOCUS with mean arterial pressure in UGIB patients.

2. Correlate the inferior vena cava diameter with the Model for End-stage Liver Disease scale in UGIB patients.

3. Correlate the inferior vena cava diameter with the 48 hours post-admission mortality of UGIB patients.

Authors design a prospective, longitudinal, descriptive study to identify the findings of TPOCUS in patients with variceal and non-variceal UGIB. Patients will be included in the study since May 15th through October 30th 2019, admitted to the University Hospital, "Dr. José E. González", Universidad Autónoma de Nuevo León.


Description:

Inclusion criteria:

1. Patients with a diagnosis of UGIB documented by endoscopy.

2. Any gender.

3. Over 18 years old.

Exclusion criteria:

1. Patients with UGIB previously treated in other hospitals.

2. Patients under 18 years of age.

3. Patients with suspected UGIB who did not undergo endoscopy.

4. Pregnant.

5. Patients with chronic obstructive pulmonary disease.

6. Patients with interstitial lung disease.

7. Patients with pleural effusion at the time of admission to the emergency room.

8. Refusal to participate in the protocol.

Method The investigators will study all patients who come to the emergency room of the hospital due to suspicion of UGIB (melena, hematemesis, vomiting in coffee grounds and hematochezia with hemodynamic instability). These patients will undergo a pulmonary and vena cava ultrasound.

Patients with suspected UGIB who are candidates for upper endoscopy during their hospital stay will undergo a second pulmonary and vena cava ultrasound ten minutes prior to upper endoscopy.

The investigators will include in the research study patients with UGIB documented by upper endoscopy. The investigators will perform a third pulmonary and vena cava ultrasound 24 hours after the endoscopic procedure.

The investigators will exclude patients with suspected UGIB but who are not candidates for endoscopy.

The technique used is a bilateral intercostal thoracic point-of-care ultrasound (TPOCUS) with the patient in supine decubitus with the head at 30 degrees. Each hemithorax will be divided into 4 areas: anterior and lateral, superior and inferior. The anterior area will be delineated between the clavicle and the diaphragm and between the parasternal line to the anterior axillary line. The lateral area will be delineated between the axilla and the diaphragm and between the anterior to the posterior axillary line. The superior area will be delineated from the 1st to the 3rd intercostal space and the lower area from the 4th to the 6th intercostal space. A total of 8 areas of the chest will be visualized during normal breathing.

The TPOCUS findings to report are:

B-type lines: Those lines are hydro-aerial artifacts presenting as comet tail images, begin in the pleural line, are hyper-echoic, well defined, disseminated towards the end of the screen, delete A-type lines, and move with the pleural slip when this it is present. The lines separated from each other around 7 mm correspond to interstitial edema, while those that distance 3 mm indicate the presence of alveolar edema. The presence of more than 3 B-type lines indicates the presence of an alveolar-interstitial syndrome.

The inferior cava vein evaluation will be performed by measuring the diameter and percentage of collapse of this vein. It will be performed in the subxiphoid window with the identification of the four cardiac chambers, then a 90ยบ turn of the transducer will made in the cephalad direction, which will show the right atrium, the union of the inferior vena cava and the liver above it. The diameter measurement will be beyond the point of confluence of the hepatic veins, usually found approximately 2 cm from the union of the inferior vena cava and the right atrium. Based on the diameter and collapse percentage measurement of the inferior vena cava on spontaneous breathing, a volume status will be defined as lack of volume if the diameter is <2 cm and the collapse percentage is >50%; however, a diameter >2 cm and a collapse percentage <50% will be classified as hypervolemic state.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date December 30, 2019
Est. primary completion date December 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Age, more than 17 years old.

- Patients diagnosed with UGIB.

- Any etiology of the UGIB.

Exclusion Criteria:

- Patients with UGIB previously treated in other hospitals.

- Patients with UGIB with Blatchford scale less than 2 points.

- Pregnant women.

- Refusal to participate in the protocol.

Study Design


Locations

Country Name City State
Mexico Hospital Universitario Dr. Jose E. Gonzalez, Universidad Autónoma de Nuevo León Monterrey Nuevo León

Sponsors (1)

Lead Sponsor Collaborator
Hospital Universitario Dr. Jose E. Gonzalez

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary B-type lines on thoracic point-of-care ultrasound in patients with UGIB. The number of B-type lines measured by thoracic point-of-care ultrasound in patients with variceal and non-variceal UGIB at 48 hours. 48 hours
Primary Diameter of inferior vena cava on thoracic point-of-care ultrasound in patients with UGIB. The diameter in centimeters of inferior vena cava measured by thoracic point-of-care ultrasound in patients with variceal and non-variceal UGIB at 48 hours. 48 hours
Secondary B-type lines and mean arterial pressure on UGIB patients To correlate the presence of B-type lines on thoracic point-of-care ultrasound with mean arterial pressure in UGIB patients. 48 hours
Secondary Inferior vena cava diameter and Model for End-stage Liver Disease on UGIB patients To correlate the inferior vena cava diameter with the Model for End-stage Liver Disease scale in UGIB patients. 48 hours
Secondary Inferior vena cava diameter and 48 hours mortality in UGIB patients. To correlate the inferior vena cava diameter with the 48 hours post-admission mortality rate in UGIB patients. 48 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02537353 - Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Phase 4
Recruiting NCT03624517 - Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices Phase 4
Suspended NCT03337256 - Direct Discharge of Patients With Upper Gastrointestinal Bleeding From the Emergency Department After Endoscopy N/A
Completed NCT04472364 - HemoPill Acute ® in Suspected Nonvariceal Upper Gastrointestinal Bleeding N/A
Completed NCT05563714 - Anticoagulation With Enhanced Gastrointestinal Safety N/A
Recruiting NCT00414713 - Transfusion Requirements in Gastrointestinal (GI) Bleeding Phase 4
Completed NCT03680950 - Efficacy Test of Real-Time Upper Gastrointestinal Monitoring System N/A
Completed NCT05085405 - Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial N/A
Recruiting NCT06077916 - Gastric CLEANsing by Intravenous AZithromycin in Urgent Endoscopy N/A
Recruiting NCT04902248 - OTSC vs. Angiographic Embolization in Patients With Refractory Non-variceal Upper Gastrointestinal Bleeding N/A
Completed NCT02446678 - Use of PillCam ESO2 in Triaging Patients Present With Upper GIB N/A
Completed NCT05631639 - Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor Capsule -A Pilot Study N/A
Completed NCT02978391 - UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD N/A
Completed NCT00045799 - Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill Phase 3
Recruiting NCT03090945 - Pediatric Acute Gastrointestinal Bleeding Registry
Recruiting NCT06192355 - Single-use Versus Reusable Gastroscopes in Patients With Upper Gastrointestinal Bleeding. N/A
Recruiting NCT06297954 - Usefulness of Metoclopramide to Improve Endoscopic Visualization in Upper Gastrointestinal Bleeding Phase 3
Recruiting NCT03785080 - Non-warfarin Oral AntiCoagulant Resumption After Gastrointestinal Bleeding in Atrial Fibrillation Patients N/A
Completed NCT03667703 - Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease Phase 4
Terminated NCT02017379 - Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed. N/A